What TauTona Group does

TauTona Group is a privately held, vertically-integrated operational fund founded in 2010 by Stanford School of Medicine professors Geoffrey C. Gurtner, MD and Michael Longaker, MD. The firm creates, invests in, and develops medtech, biotech, and regenerative-medicine assets, organizing its efforts around three clinical pillars: minimally invasive and laparoscopic surgery (TPAD pneumoperitoneum assist device, BioBolt surgical stapler, fluorescence-visible surgical marker), wound care management (TauTona Wound Dressing / TWD pullulan-collagen hydrogel, Cell Sponge cell-delivery matrix, Theris Medical Patch deferoxamine topical for sickle cell leg ulcers), and regenerative and aesthetic medicine (Adipose Tissue Injector, lyophilized HA Thread Technology, Skin Splint, Nipple Reconstruction Device). Several technologies are protected by issued US patents with international coverage, and the firm has secured FDA 510(k) clearance for TPAD and FDA Orphan Drug Designation for the Theris Medical Patch.

TauTona does not commercialize products directly to end users. Instead, it develops assets internally to de-risked milestones, then exits through strategic acquisition by large healthcare companies (e.g., Allergan acquired the Aline Aesthetics HA Thread Technology, LifeCell acquired the Adipose Tissue Injector, and Novadaq acquired the surgical marker for integration with its SPY and LUNA fluorescence imaging systems), spin-outs to NewCos, or strategic investments. The fund model is positioned as a contrarian alternative to traditional healthcare venture capital, explicitly targeting sub-$250M market opportunities that large healthcare VCs have been abandoning while Series A healthcare venture funding has fallen over 50% since 2021. Operationally, the firm shares resources across portfolio technologies to minimize overhead and routes capital directly to product development, supported by a long-term technology-licensing relationship with Stanford University.

The firm is headquartered at 604 Fifth Avenue, Suite D, Redwood City, California, with a small core team of approximately 6-50 employees including the two co-founder/managing partners, a COO with prior leadership of PRTM's US Medical Device practice, a Head of Research with postdoctoral training at Stanford, a Head of Quality and Regulatory with 25+ years at Abbott and other medtech firms, and a Marketing Development lead with prior venture experience at Canaan Partners, Draper Fisher Jurvetson, and Vanguard Ventures. No public revenue, fund size, cap table, or institutional limited-partner information is disclosed.

Name

TauTona Group

Legal name

The Tautona Group

Website

https://tautonagroup.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

TauTona Group is a privately held, vertically-integrated operational fund that develops medtech, biotech, and regenerative-medicine assets and exits them via strategic acquisition, spin-out, or strategic investment by large healthcare companies, with 9+ products developed and 3+ disclosed exits to date.

Ownership category

akta.pro rank

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Operational Fund Investment Returns: TauTona operates as a vertically-integrated operational fund. Revenue/returns generated through developing medical technologies and exiting via strategic acquisition, spin-out to NewCo, or strategic investment by larger healthcare companies. Fund dollars go directly to product development.
2. Technology Acquisitions / Exits: Exit revenue generated through the sale/acquisition of internally-developed technologies to larger healthcare companies (e.g., Allergan, LifeCell, Novadaq acquired TauTona-developed technologies).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

TauTona Group is a vertically-integrated operational fund that creates, invests in, and develops proprietary medical device, biotechnology, and regenerative medicine technologies from ideation to commercialization. The company develops these technologies internally and then exits via strategic acquisition, spin-out to a new company, or strategic investment by larger healthcare companies, with notable exits including sales to Allergan, LifeCell, and Novadaq Technologies.

Product overview

TauTona Group operates as a vertically-integrated operational fund that creates, invests in, and develops a portfolio of medical device products spanning medtech, biotech, and regenerative medicine. The offering is a portfolio of distinct, independently developed products rather than a single unified platform. Surgical tools form one cluster (the Pneumoperitoneum Assist Device / TPAD, BioBolt Surgical Stapler, and Surgical Marker), wound care and therapeutic products form a second cluster (TauTona Wound Dressing / TWD and the Theris Medical Patch), regenerative-medicine tools form a third cluster (Cell Sponge, Adipose Tissue Injector / ATI, and Skin Splint), and aesthetic and reconstructive devices form a fourth cluster (Thread Tech / Aline Aesthetics Hyaluronic Acid Thread Technology and the Nipple Reconstruction Device). Several products have reached notable regulatory milestones, including FDA 510(k) clearance for TPAD and FDA Orphan Drug Designation for the Theris Medical Patch.

Differentiator

Problem solved

Functional benefit

Brands

• Theris Medical: Wound-care sub-brand commercializing a deferoxamine-based topical patch for sickle cell leg ulcers; received FDA Orphan Drug Designation and operates its own website at therismedical.com.

Products and services

• Pneumoperitoneum Assist Device (TPAD) Vacuum-assisted surgical device applying suction to the abdominal skin to facilitate upward traction during Veress needle insertion, improving speed and safety of peritoneal access for laparoscopic surgery. Designed for surgeons and laparoscopic surgery centers. FDA 510(k) cleared.
• BioBolt Surgical Stapler Innovative surgical stapler that can pierce, manipulate, and fix a variety of meshes and tissues (including solid biologic meshes) with the speed of a stapler and strength of a suture. Eliminates sharp/metal fixation devices with closed staple loops. For hernia repair and surgical mesh fixation.
• TauTona Wound Dressing (TWD) Pullulan-collagen hydrogel wound dressing with tunable, soft biomechanical properties and biocompatibility. Lyophilizable for shelf-stability and rehydrated at point of care. Hydrogel water content exceeds 90%, providing an ideal moist wound environment. For chronic wound, surgical wound, and difficult-to-heal ulcer management.
• Theris Medical Patch Topical deferoxamine formulation (existing sickle cell drug repurposed) for treating sickle cell leg ulcers. First biopharmaceutical innovation from TauTona. Granted FDA Orphan Drug Designation; clinical trial initiated (NCT04058197). For patients with sickle cell disease and chronic leg ulcers.
• Thread Tech (Aline Aesthetics Hyaluronic Acid Thread Technology) Patented platform converting liquid hyaluronic acid to a solid-state, resorbable thread (freeze-dried). Thread attached to a needle is placed beneath wrinkles, rehydrates and smooths the wrinkle from the inside. Avoids neurological side effects of biotoxins. For aesthetic and cosmetic applications; acquired by Allergan.
• Cell Sponge (Pullulan/Soft Collagen Matrix) Novel pullulan-collagen hydrogel with tunable, soft biomechanical properties and biocompatibility for cell-based therapy encapsulation. Combines pullulan (a linear homopolysaccharide produced by fungus Aureobasidium pullulans) with Type 1 collagen. Serves as a cost-effective dressing and cell therapy delivery system. For regenerative medicine and stem cell delivery.
• Nipple Reconstruction Device System Series of soft silicone molds that gently pull and stretch skin to gradually form a nipple from the surface of a reconstructed breast. Each mold progressively pulls more tissue until desired size is achieved. For breast reconstruction patients following mastectomy.
• Adipose Tissue Injector (ATI) Automated injection device for fat grafting that controls injection pressure and flow rate to deliver pre-programmed sized aliquots. Single-use sterile device with battery power for more than 1 liter of tissue delivery (>10,000 1ul aliquots). Includes sophisticated clog detection feature. Acquired by LifeCell.
• Skin Splint (Cellulite Treatment System) Patented system combining septae cutting with a high-tech, structured silicone patch (dermal splint) that holds skin surface flat during healing for a smoother post-cellulite treatment outcome. For aesthetic and dermatological applications.
• Fluorescence-Visible Surgical Marker Patented pen whose tip is visible on fluorescence imaging display, allowing surgeons to mark areas of interest visible under fluorescence imaging regardless of lighting conditions. Designed for use with ICG and SPY/LUNA imaging systems. Acquired by Novadaq Technologies.

Quantifiable outcome

• Reduces hernia repair suturing process from 30-60 minutes to 5 minutes using BioBolt Surgical Stapler
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• AllerganflagshipStrategic or Co-development PartnerAllergan, the creators of Botox, acquired TauTona's Aline Aesthetics Hyaluronic Acid (HA) Thread Technology with plans to integrate the threads technology into their aesthetic product portfolio. Allergan is a major pharmaceutical/aesthetics company.
• LifeCellflagshipStrategic or Co-development PartnerLifeCell acquired TauTona's Adipose Tissue Injector (ATI) technology. LifeCell is a medical devices / regenerative medicine company.
• Novadaq TechnologiesflagshipStrategic or Co-development PartnerNovadaq Technologies, a leading developer of clinical fluorescence imaging solutions for surgical and outpatient wound care, acquired the TauTona surgical marker technology. Novadaq expected to integrate the technology into their SPY and LUNA fluorescence imaging products, which are recognized by more than 70 peer-reviewed publications.
• Stanford UniversitycoreStrategic or Co-development PartnerTauTona was founded in 2010 by two Stanford School of Medicine professors (Geoffrey Gurtner, MD and Michael Longaker, MD). TauTona licenses technology from Stanford research labs and the co-founders maintain their faculty positions. Key technologies including Theris Medical Patch and Cell Sponge are based on research from Dr. Gurtner's lab at Stanford.
• Aline Aesthetics (acquired by Allergan)minorOEM/ Whitelabel/ Licensing PartnerAline Aesthetics was the brand under which TauTona's HA Thread Technology was commercialized before being acquired by Allergan.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OrbiMed: Healthcare-focused investment firm that invests across the medtech, biotech, and healthcare services continuum with deep operating expertise — directly comparable to TauTona's medtech/biotech focus and active development approach.
• Frazier Healthcare Partners: Healthcare-dedicated private equity and venture firm with an operational, company-creation model (e.g., Frazier Life Sciences) that develops and invests in medtech, biotech, and pharma — directly comparable to TauTona's vertically-integrated operational fund approach.
• Longitude Capital: Healthcare-dedicated growth and venture investment firm that finances commercial-stage and late-development medical device, biotech, and healthcare services companies — directly comparable to TauTona's medtech/biotech focus and exit-oriented strategy.
• Domain Associates: Healthcare-only venture firm that finances and builds therapeutic and medical-device companies from inception through commercialization — directly comparable to TauTona's healthcare-exclusive, build-oriented investment model.
• Versant Ventures: Healthcare-focused venture firm that creates, invests in, and builds biotech, medtech, and healthcare services companies — closely comparable to TauTona's operational, build-from-ideation model in medtech and biotech.

Broad incumbents

• HealthCare Royalty Partners: Healthcare-focused investment firm that acquires and finances healthcare-related assets and royalties; broader and more financially structured than TauTona but operates in the same healthcare investment space with similar exit-driven economics.
• Deerfield Management: Healthcare investment firm that supports companies across the lifecycle in therapeutics, medtech, and healthcare services; larger and more diversified than TauTona, but operates with a similar commitment to advancing medical innovation through investment.
• Integra LifeSciences: Established medical device company with a portfolio in regenerative medicine, wound care, and surgical technologies (including assets acquired from smaller developers) — comparable to the kind of strategic acquirer that TauTona targets, and overlapping in wound care and regenerative product categories.
• NEA (New Enterprise Associates): Large multi-stage venture firm with a significant healthcare practice that invests in and helps build medtech and biotech companies; broader and more diversified than TauTona but operates with similar development-oriented intent in healthcare.

Regional players

• Inova Health System / Inova Strategic Investments: Integrated health system with a strategic investment arm that supports medtech and healthcare innovation — comparable in its healthcare-development orientation though regionally focused and not a pure operational fund.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tautona-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TauTona Group